Practical algorithms for amyloid β probability in subjective or mild cognitive impairment
Abstract
Practical algorithms predicting the probability of amyloid pathology among patients with subjective cognitive decline or mild cognitive impairment may help clinical decisions regarding confirmatory biomarker testing for Alzheimer's disease.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2019
- Source ID
- 10.1016/j.dadm.2019.09.001
Entities
People
- Alzheimer's Disease Neuroimaging Initiative And The Aibl Research Team
- Clifford Jack
- Feng Gao
- Jeremiah A. Aakre
- Jeremy A. Syrjanen
- Judith Jaeger
- Michelle M. Mielke
- Nancy Maserejian
- Shijia Bian
- Wenting Wang
Organizations
- Albert Einstein College of Medicine
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Department of Health and Social Care
- Eisai
- Eli Lilly and Company
- GE HealthCare
- Hoffmann-La Roche
- Laboratoires Servier
- Mayo Clinic
- Medpace
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Novartis
- Perrigo Company Plc
- Pfizer
- Roche (United States)
- United States Department of Defense